Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There has been a rash of low float runs happening in the last few days. This is likely another.
Kinda sad. Used to be fun. Now life is just the grind of trading in boredom.
Anyone here have Christmas? Merry or otherwise?
Doesn’t mean anything. Year end adjustments or perhaps last minute loss capture. ‘Tis the season to not take much serious.
Obviously taking a pass on it below 50 and again at about 100 was the wisest choice. NOT!!! But at least consistent with much of the rest of my investing activity.
Sorry, you past the passed out time. You obviously need some practice.
A 10% stock dividend is 10% dilution isn’t it? Been down that road before.
So.......BRIG either just got vaccinated or just figured out that you can’t catch covid from a monitor and that he had been taking that social distancing thing a bit too far.
still kicking I see.
it ran
every time HALO gets an approval REPR's TAM goes up.
sounds like the wave of the future. in home med is so much cheaper that in a med facility. I think the market is enormous
some favorable news about new tech in medication.
Halozyme Therapeutics (NASDAQ:HALO)
Intraday Stock Chart
Today : Friday 13 September 2019
SAN DIEGO, Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated a fixed-dose combination of pertuzumab (Perjeta®) and trastuzumab (Herceptin®) for subcutaneous administration using Halozyme's ENHANZE® drug delivery technology in combination with intravenous chemotherapy. The study results demonstrated non-inferior levels of Perjeta® in the blood (pharmacokinetics) compared to standard intravenous (IV) infusion of Perjeta® plus Herceptin® and chemotherapy in patients with HER2-positive early breast cancer.
"The results of the phase III FeDeriCa study represent an important development for our ENHANZE® drug delivery technology," said Dr. Helen Torley, President and CEO. "This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing our ENHANZE® technology, thereby providing patients with HER2-positive breast cancer the possibility of a faster treatment option."
Subcutaneous administration of the fixed-dose combination of Perjeta® and Herceptin® is approximately 8 minutes for the initial loading dose and approximately 5 minutes for each subsequent maintenance dose. Intravenous administration is approximately 150 minutes for the loading dose of Perjeta® and Herceptin® using standard IV formulations and between 60-150 minutes for subsequent maintenance infusions for the combination.
The study also demonstrated that the safety profile of the fixed dose subcutaneous combination of Perjeta® and Herceptin® was consistent with the safety profile of Perjeta® and Herceptin® administered intravenously.
Full data from the FeDeriCa study will be submitted for presentation at an upcoming medical meeting and to health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).1 2
About ENHANZE® Technology
Halozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. ENHANZE® may also benefit subcutaneous biologics by reducing the need for multiple injections. This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
never ran across that until about 3 days ago.
yes, it's way ahead of fundies. flying on hopium. however much of that hopium is justified so I don't expect a sudden collapse.
that euphoria might break today. third day of the third breakout and parabolic at that.
still have half of my original position. .25 to 2.5 was enough to loosen my grip a bit. may reload some when the euphoria breaks.
that chart does look scary.
crickets
yep.....a dube in every bag of taco chips.
got a little "krafty" with the books it seems. poor warren!!!
that is what I see. I think that that is a good portion of the reason for the recent interest in the company.
new management may be a major plus here. but we can't ignore the fact that every drug regimen that is approved by the FDA for infusion opens increasing markets for REPR. they have made note of the purchases by drug companies for the purposes of trials in this area. HALO's ability to create infusible formulations out of regimens that require injection is being tested in an increasing number of trials. I would expect to see a rapidly increasing addressable market for REPR. it seems logical that others see that as well. REPR may well become a takeover or a take private target. I wouldn't like either.
Halozyme Theraputics.
take a look at HALO and see if what they are doing might translate to an increase in TAM for REPR. that may in part explain some of the rise.
"sales to pharmaceutical companies. (.3m?) I think this might be important. "
indeed it is. there are a number of studies that have been started to try and convert drugs that required intra venous administration into forms that can be infused. REPR may be on the cusp of a large increase in their total addressable market.
as long as you don't get complaints from siri.....
sorta like Brigg's social decorum
I think it was buzz, I think.
who said you could think?
anytime an officer suddenly quits his post before a replacement is in place is bothersome to me. that being said, the recent interest here may be in part the result of a massive increase in addressable market with the HALO product being used to create infusion formulations.
OOOOOOPPPPPS!!!!
mispushed the 'F' button.
if it had actually been the CFO, it would have more than bothered me. I would be out of the stock. the wondering why there was an abrupt leaving is the bothersome part. where there is a wondering why, there is upcoming weakness in the stock. if mistakes were made, they will be either be paid for by us or the corrections will benefit us. the market hates uncertainty.
I am somewhat concerned by the abrupt departure of the CFO but encouraged by recent insider buying.
they are now licensing tech to big pharma that allows some drugs that now require intravenous delivery to be delivered with subcutaneous infusion.
HALO may have something to do with it. also clearing up the FDA letter.
a ten year old can only do so much
nothing so cruel. the startled squeals of those who found their backside subject to the application of said needle was reward enough.
I remember making weapons out of pens. remove the toggle mechanism from the top half, install the ignition section of a party popper with the string hanging out of the end where the push button was, followed by a projectile made from a heavy duty needle with a small wad of cotton inserted thru the eye.
but there is nothing like 40cal for immediacy.